1. Home
  2. DXR vs RNTX Comparison

DXR vs RNTX Comparison

Compare DXR & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Daxor Corporation

DXR

Daxor Corporation

HOLD

Current Price

$10.50

Market Cap

59.0M

Sector

Health Care

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.15

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXR
RNTX
Founded
1970
2001
Country
United States
United States
Employees
N/A
10
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.0M
47.7M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
DXR
RNTX
Price
$10.50
$1.15
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
9.2K
1.1M
Earning Date
02-27-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,446,345.00
N/A
Revenue This Year
$44,935.22
N/A
Revenue Next Year
$74.79
N/A
P/E Ratio
$33.83
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.47
$1.00
52 Week High
$14.76
$2.22

Technical Indicators

Market Signals
Indicator
DXR
RNTX
Relative Strength Index (RSI) 52.35 40.08
Support Level $9.33 $1.09
Resistance Level $11.23 $1.30
Average True Range (ATR) 0.91 0.12
MACD 0.01 -0.03
Stochastic Oscillator 43.59 19.12

Price Performance

Historical Comparison
DXR
RNTX

About DXR Daxor Corporation

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: